Skip to main content

Table 1 Percentage of H-460 cells in late or early apoptosis at the end of treatment period either with doxorubicin or P276-00 alone or in the combination of doxorubicin followed by P276-00

From: Potentiation of in vitro and in vivoantitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

Treatment group Percentage of cells
  Live cells Annexin +ve Annexin + PI PI +ve
Control 90.5 3 4 2.3
Doxorubicin ( 100 nM) 60 30.4 8.6 1
P276-00 (1200 nM) 53 38.5 8.2 0.3
Doxorubicin> P276-00 14.1 50.2 34.3 2